Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on March 9, 2021. The filing serves as a Regulation FD disclosure regarding a corporate presentation made available to attendees of the virtual H.C. Wainwright Global Life Sciences Conference and the 33rd Annual Roth Conference.
Financial Metrics
This filing does not contain specific financial data. The document explicitly states that the information provided, including the attached presentation (Exhibit 99.1), is not deemed "filed" for purposes of Section 18 of the Exchange Act. Consequently, no revenue, profit, cash flow, margin, debt, or liquidity figures are reported within this text.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the availability of a management presentation.
Guidance, Outlook, and Risks
The filing references a corporate presentation by senior management but does not summarize its contents, guidance, or outlook within the text of the 8-K. The filing includes a standard disclaimer that the presentation materials are not incorporated by reference into any Securities Act or Exchange Act filings.
Key Facts for Investor Verification
- Verify the content of the attached "Cocrystal Pharma, Inc. Corporate Presentation, dated March 2021" (Exhibit 99.1) for actual financial updates or strategic guidance.
- Note that the presentation materials are not legally "filed" with the SEC and are not subject to the liabilities of Section 18 of the Exchange Act.
- Confirm the company's status as a Nasdaq Capital Market listed entity (Symbol: COCP).